Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

28,119 26,813

Interest income and

other, net 864 1,189 2,855 3,402

Net income (loss) (2) $12,307 $(6,259) $(1,372) (19,142)

Net loss per share,

basic and diluted (2) $0.43 $(0.22) $(0.05) $(0.67)

Share used in

calculating net loss

per share, basic and

diluted 28,651 28,562 28,637 28,489

(1) Includes $77 and ($1,897) as additional (reduction in) research and

development expense, which represents an estimate of the net payable

due to (reimbursement by) Novartis of ANA975 research and development

costs for the three months ended September 30, 2007 and 2006,

respectively. Includes ($514) and ($3,423) as an offset in research

and development expense, which represents an estimate of the net

reimbursement by Novartis of ANA975 research and development costs for

the nine months ended September 30, 2007 and 2006, respectively.

(2) Includes non-cash operating expenses of $1,392 and $2,010 determined

in accordance with Statement of Financial Accounts Standards No.

123(R), "Share-Based Payment" (SFAS No. 123(R)) or approximately $0.05

and $0.07 effect on basic and diluted net income (loss) per common

share for the three months ended September 30, 2007 and 2006,

respectively. Research and development expense and general and

administrative expense includes $969 and $423 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the three

months ended September 30, 2007. Includes non-cash operating expenses

of $3,502 and $4,951 determined in accordance with Financial Accounts

Standards Board Statement 123(R), "Share-Based Payment" or

approximately $0.12 and $0.17 effect on basic and diluted net l
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 The College ... first private college in the Mid-Hudson Region to be ... now begin accepting applications from qualified “high-technology” businesses that ... are very pleased to have been selected for the ... Cuomo’s transformative initiative to stimulate economic development in New ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Wis. - For the first time in the team's history, ... ranked first in the nation, giving Wisconsin fans just one more ... and I know the team will enjoy tremendous support from everyone ... University of Wisconsin System shouldn't begin or end with the ...
... Wis. - Paul Hager admits the technology associated ... proprietary ways to address its flaws and transform it ... early-stage Madison business called VoVison , has ambitious ... three differentiating features: a hosted solution, plus self-correction and ...
... since DEMO 2007, I've had the chance to play a ... Jaman.com . Launched at the conference, Jaman.com offers a growing ... at prices that average about $6 per film. , ,While ... the Jaman.com experience is the downloadable player, a desktop application ...
Cached Biology Technology:Fueling our economy with the University of Wisconsin 2Fueling our economy with the University of Wisconsin 3Fueling our economy with the University of Wisconsin 4Tech upstart VoVision could disrupt the voice-recognition market 2Tech upstart VoVision could disrupt the voice-recognition market 3Tech upstart VoVision could disrupt the voice-recognition market 4We're "Jaman": Purpose-driven browsers drive next wave of Web applications 2We're "Jaman": Purpose-driven browsers drive next wave of Web applications 3
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
(Date:8/22/2014)... to purchase fuel cell cars from Toyota and other ... cars will run on hydrogen made from natural gas, ... Now scientists at Stanford University have developed a low-cost, ... produce hydrogen by water electrolysis. The battery sends ... water into hydrogen and oxygen gas. Unlike other water ...
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... The Tyler Prize for Environmental Achievement today named Diana H. ... 2013 Tyler Prize for her research documenting and exploring the ... from more than 20 years in Antarctica,s deserts, to the ... has explored the dynamics of species like nematodes, small worm-like ...
... Swarming is the spontaneous organised motion of a large number ... colonies, slime moulds and groups of insects to shoals of ... Romenskyy and Vladimir Lobaskin from University College Dublin, Ireland, have ... just published in EPJ B . Ultimately, this could ...
... spinoff of research at Case Western Reserve University, has ... to develop a medical device for bladder control. ... function lost due to injury or illness. Patients with ... likely to be the first to benefit from the ...
Cached Biology News:Antarctic soil researcher awarded prestigious 2013 Tyler Environmental Prize 2Antarctic soil researcher awarded prestigious 2013 Tyler Environmental Prize 3Antarctic soil researcher awarded prestigious 2013 Tyler Environmental Prize 4Antarctic soil researcher awarded prestigious 2013 Tyler Environmental Prize 5CWRU spinoff ConservoCare gets licensing options to develop medical device for bladder control 2CWRU spinoff ConservoCare gets licensing options to develop medical device for bladder control 3
...
Recombinant Feline IFN-alpha...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Biology Products: